Humacyte Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $3.68
- Today's High:
- $4.1498
- Open Price:
- $3.9
- 52W Low:
- $1.96
- 52W High:
- $5.6
- Prev. Close:
- $3.7
- Volume:
- 1872818
Company Statistics
- Market Cap.:
- $417.88 million
- Book Value:
- 0.591
- Revenue TTM:
- $31000
- Operating Margin TTM:
- -291677.42%
- Gross Profit TTM:
- $1.57 million
- Profit Margin:
- 0%
- Return on Assets TTM:
- -27.27%
- Return on Equity TTM:
- -87.2%
Company Profile
Humacyte Inc had its IPO on 2021-08-26 under the ticker symbol HUMA.
The company operates in the Healthcare sector and Biotechnology industry. Humacyte Inc has a staff strength of 164 employees.
Stock update
Shares of Humacyte Inc opened at $3.9 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $3.68 - $4.15, and closed at $3.88.
This is a +4.86% increase from the previous day's closing price.
A total volume of 1,872,818 shares were traded at the close of the day’s session.
In the last one week, shares of Humacyte Inc have slipped by -3.96%.
Humacyte Inc's Key Ratios
Humacyte Inc has a market cap of $417.88 million, indicating a price to book ratio of 2.3983 and a price to sales ratio of 153.9075.
In the last 12-months Humacyte Inc’s revenue was $31000 with a gross profit of $1.57 million and an EBITDA of $-82215000. The EBITDA ratio measures Humacyte Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Humacyte Inc’s operating margin was -291677.42% while its return on assets stood at -27.27% with a return of equity of -87.2%.
In Q2, Humacyte Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 100%.
Humacyte Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-0.89 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Humacyte Inc’s profitability.
Humacyte Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 3.3809. Its price to sales ratio in the trailing 12-months stood at 153.9075.
Humacyte Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $168.11 million
- Total Liabilities
- $11.39 million
- Operating Cash Flow
- $1.62 million
- Capital Expenditure
- $485000
- Dividend Payout Ratio
- 0%
Humacyte Inc ended 2024 with $168.11 million in total assets and $0 in total liabilities. Its intangible assets were valued at $168.11 million while shareholder equity stood at $61.12 million.
Humacyte Inc ended 2024 with $2.39 million in deferred long-term liabilities, $11.39 million in other current liabilities, 10000.00 in common stock, $-486213000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $114.60 million and cash and short-term investments were $114.60 million. The company’s total short-term debt was $2,455,000 while long-term debt stood at $36.25 million.
Humacyte Inc’s total current assets stands at $120.56 million while long-term investments were $0 and short-term investments were $0.00. Its net receivables were $0.00 compared to accounts payable of $2.36 million and inventory worth $0.
In 2024, Humacyte Inc's operating cash flow was $1.62 million while its capital expenditure stood at $485000.
Comparatively, Humacyte Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $3.88
- 52-Week High
- $5.6
- 52-Week Low
- $1.96
- Analyst Target Price
- $7.25
Humacyte Inc stock is currently trading at $3.88 per share. It touched a 52-week high of $5.6 and a 52-week low of $5.6. Analysts tracking the stock have a 12-month average target price of $7.25.
Its 50-day moving average was $3.37 and 200-day moving average was $3.19 The short ratio stood at 6.48 indicating a short percent outstanding of 0%.
Around 3969.9% of the company’s stock are held by insiders while 1204% are held by institutions.
Frequently Asked Questions About Humacyte Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.